Observational studyPloS one2026
Evaluation of antibacterial agent use in adult patients at a tertiary-level hospital in Jordan: A comparative analysis of defined daily dose and days of therapy in critical care units.
Observational study in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare two measures of antibiotic stewardship: Defined Daily Dose (DDD) versus Days of Therapy (DOT).
methodsRetrospective observational analysis of clinical data for adult ICU patients with antimicrobial exposure recorded from July 2023 to July 2024. The variables collected were the DDD and DOT. The DDD variable was defined according to the World Health Organization (WHO) standards for all antibacterial medications. For the DOT variable, DOTs reflected each day a drug was given, regardless of dose count. For comparability, total DDDs and DOTs were standardized per 100 patient-days using the 6,614 patient-days accrued by the antimicrobial-exposed ICU cohort as the denominator.
resultsOver the study duration, 1,024 patients were admitted to adult ICUs, of whom 607 received antimicrobial agents. The overall median total DDD per antimicrobial agent was 64.3 (interquartile range [IQR]: 6.6-530.0), while the corresponding median total DOT was 47.0 (IQR: 6.0-581.5), reflecting considerable variation in absolute antimicrobial measurement across the two methods (Wilcoxon signed-rank test across patient-antimicrobial pairs: V = 130,979, p < 0.001).
conclusionsDDD and DOT remained strongly correlated but showed clinically meaningful drug-level disagreement in this ICU cohort. DOT provides a clinically interpretable measure of antimicrobial exposure duration in ICU patients because it reflects treatment days irrespective of dose, whereas DDD remains useful for standardized benchmarking across institutions and time periods. The two measures provide complementary information on antimicrobial use and should not be interpreted as substitutes for one another.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.